Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MECLOFENAMATE SODIUM vs ACETAMINOPHEN AND IBUPROFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.
Relief of mild to moderate acute pain,Treatment of primary dysmenorrhea,Management of osteoarthritis,Management of rheumatoid arthritis
Temporary relief of minor aches and pains,Reduction of fever,Off-label: Management of osteoarthritis pain, headache, dysmenorrhea
50 mg or 100 mg orally three times daily; maximum 400 mg/day.
Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.
2-4 hours (terminal half-life; may be prolonged in hepatic impairment or elderly)
Acetaminophen: 2-3 hours (normal hepatic function). Ibuprofen: 2-4 hours (immediate-release); prolonged in overdose or hepatic impairment.
Primarily hepatic via cytochrome P450 enzymes, including CYP2C9 and CYP3A4.
Acetaminophen is primarily metabolized via glucuronidation and sulfation; a minor pathway via CYP2E1 produces a toxic metabolite, NAPQI. Ibuprofen is metabolized primarily by CYP2C9 and to a lesser extent by CYP2C8.
Renal (60-70% as metabolites and conjugates), biliary/fecal (20-30%)
Acetaminophen: renal excretion of metabolites (glucuronide 55%, sulfate 30%, cysteine/mercapturate <10%); <5% unchanged. Ibuprofen: renal excretion of metabolites (conjugates) 90%; <10% unchanged; minor biliary/fecal.
>99% (primarily to albumin)
Acetaminophen: 10-25% (albumin). Ibuprofen: >99% (albumin).
0.5-1.0 L/kg (indicates extensive tissue distribution)
Acetaminophen: 0.9 L/kg; Ibuprofen: 0.15 L/kg (highly protein-bound, low Vd).
100% (oral, well absorbed)
Acetaminophen: 75-85% oral. Ibuprofen: 80-100% oral.
e GFR 30-59 m L/min: use with caution, reduce dose by 50%; e GFR <30 m L/min: contraindicated.
GFR 30-59: Caution, use lowest effective dose; GFR <30: Contraindicated due to ibuprofen component.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh A: No adjustment; Child-Pugh B: Caution, reduce acetaminophen dose; Child-Pugh C: Contraindicated.
Not recommended for children under 14 years; for adolescents ≥14 years, same as adult dosing.
Weight-based: 10-15 mg/kg acetaminophen + 5-10 mg/kg ibuprofen per dose, every 6-8 hours, max 4 doses/day.
Initiate at lowest effective dose (50 mg twice daily); monitor renal function and GI bleeding risk.
Use lowest effective dose; monitor renal function due to ibuprofen; avoid durations >10 days.
NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. Meclofenamate is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Acetaminophen may cause severe liver injury, including acute liver failure, at doses exceeding 4,000 mg/day. Ibuprofen: NSAIDs increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. NSAIDs also increase risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of stomach or intestines.
Cardiovascular thrombotic events,Gastrointestinal bleeding, ulceration, and perforation,Hypertension and edema,Renal toxicity,Anaphylactoid reactions,Exacerbation of asthma,Hematologic toxicity including anemia,Hepatic enzyme elevations
Acetaminophen: Hepatotoxicity risk with excessive doses, use with caution in hepatic impairment, avoid with alcohol use >3 drinks/day. Ibuprofen: Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, fluid retention, avoid late pregnancy.
Hypersensitivity to meclofenamate or any other NSAID,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Perioperative pain in setting of CABG surgery,Active peptic ulcer disease or gastrointestinal bleeding
Acetaminophen: Severe hepatic impairment, allergy to acetaminophen. Ibuprofen: Hypersensitivity to ibuprofen or other NSAIDs, history of asthma/urticaria after NSAIDs, perioperative pain in CABG surgery, severe heart failure, active GI bleeding, late pregnancy.
Avoid high-fat meals as they may delay absorption. Limit salt intake to reduce fluid retention. Do not consume alcohol as it increases the risk of GI bleeding. Meclofenamate may decrease the effectiveness of diuretics and antihypertensive medications when taken with potassium-rich foods; monitor potassium levels.
Avoid alcohol; take with food or milk to minimize GI irritation. No specific food restrictions.
Avoid in 1st and 2nd trimester; contraindicated in 3rd trimester due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. Associated with cardiovascular malformations if used in 1st trimester.
First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibuprofen is relatively safe but may cause oligohydramnios. Third trimester: Acetaminophen is safe; ibuprofen is contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
Excreted into breast milk in small amounts; M/P ratio not established. Use caution due to potential adverse effects in neonates (e.g., gastrointestinal bleeding, platelet dysfunction).
Acetaminophen: low levels in breast milk, M/P ratio ~0.9; considered compatible with breastfeeding. Ibuprofen: minimal excretion, M/P ratio ~0.01; considered compatible. Combination: low risk with recommended doses.
Increased plasma volume may require dose adjustments in 2nd and 3rd trimesters, but specific studies lacking; generally avoid use. If necessary, use lowest effective dose for shortest duration.
No standard adjustment for acetaminophen; ibuprofen dosing unchanged in pregnancy but avoid in third trimester; consider increased clearance of acetaminophen in pregnancy but no dose adjustment recommended.
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) used for mild to moderate pain, dysmenorrhea, and inflammatory arthropathies. It has a higher incidence of gastrointestinal (GI) side effects, especially diarrhea, which can be dose-limiting. Monitor renal function and blood pressure, as it may cause fluid retention and worsening of hypertension. Use with caution in patients with a history of peptic ulcer disease or bleeding disorders. It is contraindicated in perioperative pain in coronary artery bypass graft (CABG) surgery.
Combination product for acute pain; fixed-dose may exceed recommended daily acetaminophen limit if other acetaminophen-containing products are used. Onset of ibuprofen is 30-60 min, acetaminophen 15-30 min; duration 4-6 hours. Caution in renal impairment (ibuprofen) and hepatic impairment (acetaminophen). Avoid in third trimester of pregnancy.
Take with food or milk to reduce stomach upset.,Avoid alcohol and aspirin while taking this medication.,Report signs of GI bleeding (black, tarry stools; blood in vomit) immediately.,May cause diarrhea; notify your doctor if it becomes severe or persistent.,Do not take with other NSAIDs without consulting your doctor.,Stay hydrated, but avoid excessive salt intake to prevent fluid retention.,Inform your doctor if you have kidney disease, high blood pressure, or a history of stomach ulcers.,Do not use during pregnancy, especially in the third trimester.
Do not exceed 10 tablets (500 mg acetaminophen/200 mg ibuprofen) per day.,Do not take with other products containing acetaminophen or NSAIDs.,Take with food or milk to reduce stomach upset.,Avoid alcohol while taking this medication.,Seek medical help if pain persists >10 days or fever >3 days.,Store at room temperature, away from moisture.
No interactions on record
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MECLOFENAMATE SODIUM vs ACETAMINOPHEN AND IBUPROFEN, answered by our medical review team.
MECLOFENAMATE SODIUM is a NSAID that works by Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.. ACETAMINOPHEN AND IBUPROFEN is a NSAID that works by Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MECLOFENAMATE SODIUM and ACETAMINOPHEN AND IBUPROFEN depend on the specific clinical indication. These are both NSAID agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MECLOFENAMATE SODIUM is: 50 mg or 100 mg orally three times daily; maximum 400 mg/day.. The standard adult dose of ACETAMINOPHEN AND IBUPROFEN is: Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MECLOFENAMATE SODIUM and ACETAMINOPHEN AND IBUPROFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MECLOFENAMATE SODIUM is classified as Category C. Avoid in 1st and 2nd trimester; contraindicated in 3rd trimester due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. Associated w. ACETAMINOPHEN AND IBUPROFEN is classified as Category D/X. First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibup. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.